Table 1.
NMA intervention and comparators
| Therapeutic class | Drug dose and frequency of administration |
|---|---|
| Intervention | |
| IL-17A/17Fi | Bimekizumab 160 mg Q4W |
| Comparators | |
| IL-17Ai | Secukinumab 150 mg with or without loading dose Q4W or 300 mg Q4W, ixekizumab 80 mg Q4W |
| IL-23i | Guselkumab 100 mg every Q4W or Q8W, risankizumab 150 mg Q4Wa |
| IL-12/23i | Ustekinumab 45 mg or 90 mg Q12W |
| TNFi | Adalimumab 40 mg Q2W, certolizumab pegol 200 mg Q2W or 400 mg Q4W pooled, etanercept 25 mg twice a week, golimumab 50 mg s.c. Q4W or 2 mg/kg i.v. Q8W, infliximab 5 mg/kg on weeks 0, 2, 6, 14, 22 |
| CTLA4-Ig | Abatacept 150 mg Q1W |
| JAKi | Tofacitinib 5 mg BID, upadacitinib 15 mg QD |
| PDE-4i | Apremilast 30 mg BID |
| Other | Placebo |
a
See Supplementary Table S4, available at Rheumatology online for additional dosing schedules used in included studies. BID: twice daily; CTLA4-Ig: cytotoxic T lymphocyte antigen 4-immunoglobulin; IL-17A/17Fi: IL-17A/17F inhibitor; IL-17Ai: IL-17A inhibitor; IL-12/23i: IL-12/23 inhibitor; IL-23i: IL-23 inhibitor; JAKi: Janus kinase inhibitor; NMA: network meta-analysis; PDE-4i: phosphodiesterase-4 inhibitor; Q1W: once weekly; Q2W: every 2 weeks; Q4W: every 4 weeks; Q8W: every 8 weeks; Q12W: every 12 weeks; QD: once daily; TNFi: TNF inhibitor.